Art. -Nr.: HY-B2230

Hinokitiol

(Synonyms: β-Thujaplicin)

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

Hinokitiol is a component of essential oils isolated from Chymacyparis obtusa, reduces Nrf2 expression, and decreases DNMT1 and UHRF1 mRNA and protein expression, with anti-infective, anti-oxidative, and anti-tumor activities.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 499-44-5
Formel: C₁₀H₁₂O₂
Molecular Weight:164.20

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Hinokitiol Chemical Structure

CAS. Nr.: 499-44-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]

DNMT1

Nrf2

Alle DNA Methyltransferase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BXPC-3	GI₅₀	19 μM Compound: beta-tj	Cytotoxicity against human BxPC3 cells after 72 hrs by MTS assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTS assay	[PMID: 24900743]
Ehrlich	IC₅₀	0.6 μg/mL Compound: Hinokitiol	Cytotoxicity against mouse Ehrlich cells after 72 hrs by MTT assay Cytotoxicity against mouse Ehrlich cells after 72 hrs by MTT assay	[PMID: 11975498]
FM3A	IC₅₀	1.1 μM Compound: 1	Inhibit growth of FM3A cells by 50% Inhibit growth of FM3A cells by 50%	[PMID: 1732542]
G-361	IC₅₀	8.98 μM Compound: beta-Thujaplicin	Competitive inhibition of tyrosinase in human G-361 cells incubated for 10 mins measured for 2 hrs by MBTH-based spectrophotometry Competitive inhibition of tyrosinase in human G-361 cells incubated for 10 mins measured for 2 hrs by MBTH-based spectrophotometry	[PMID: 25288494]
HCT-116	GI₅₀	6.92 μM Compound: beta-tj	Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 24900743]
HCT-116	IC₅₀	4.5 μM Compound: 1, Hinokitiol, beta-thujaplicin	Cytotoxicity against human HCT116 cells after 24 to 72 hrs Cytotoxicity against human HCT116 cells after 24 to 72 hrs	[PMID: 24308647]
HL-60	IC₅₀	0.3 μg/mL Compound: Hinokitiol, beta-thujaplicin	Cytotoxicity against Homo sapiens (human) HL60 Cytotoxicity against Homo sapiens (human) HL60	[PMID: 15187442]
HT-22	EC₅₀	4.8 μM Compound: beta-thujaplicin	Neuroprotective activity against glutamate-mediated oxidative stress-induced cell death in mouse HT22 cells assessed as survival after 24 hrs by MTT assay Neuroprotective activity against glutamate-mediated oxidative stress-induced cell death in mouse HT22 cells assessed as survival after 24 hrs by MTT assay	[PMID: 20045220]
HuT78	GI₅₀	4.99 μM Compound: beta-tj	Cytotoxicity against human HUT78 cells after 72 hrs by MTS assay Cytotoxicity against human HUT78 cells after 72 hrs by MTS assay	[PMID: 24900743]
Jurkat	GI₅₀	1.1 μM Compound: beta-tj	Cytotoxicity against human Jurkat cells after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells after 72 hrs by MTS assay	[PMID: 24900743]
K562	IC₅₀	0.3 μg/mL Compound: Hinokitiol, beta-thujaplicin	Cytotoxicity against Homo sapiens (human) K562 Cytotoxicity against Homo sapiens (human) K562	[PMID: 15187442]
KB	IC₅₀	3.5 μM Compound: 1	Inhibit growth of KB cells by 50% Inhibit growth of KB cells by 50%	[PMID: 1732542]
SW-620	IC₅₀	4.4 μM Compound: 1, Hinokitiol, beta-thujaplicin	Cytotoxicity against human SW620 cells after 24 to 72 hrs Cytotoxicity against human SW620 cells after 24 to 72 hrs	[PMID: 24308647]
T98G	IC₅₀	152.5 μM Compound: Hinokitiol	Inhibition of cell viability in human T98G cells incubated for 24 hrs by MTT assay Inhibition of cell viability in human T98G cells incubated for 24 hrs by MTT assay	[PMID: 39241669]
U-87MG ATCC	IC₅₀	316.5 μM Compound: Hinokitiol	Inhibition of cell viability in human U-87 MG cells incubated for 24 hrs by MTT assay Inhibition of cell viability in human U-87 MG cells incubated for 24 hrs by MTT assay	[PMID: 39241669]

In Vitro

In U87MG and T98G glioma cell lines, hinokitiol demonstrates a dose-dependent decrease in viability, with IC₅₀ values of 316.5 ± 35.5 and 152.5 ± 25.3 μM, respectively. Hinokitiol represses ALDH activity and self-renewal ability in glioma stem cells, and inhibits in vitro oncogenicity. Hinokitiol also reduces Nrf2 expression in glioma stem cells in a dose-dependent manner^[1]. Hinokitiol (0-100 μM) inhibits colon cancer cell growth in a dose- and time-dependent manner. Hinokitiol (5, 10 μM) decreases DNMT1 and UHRF1 mRNA and protein expression, and increases TET1 expression via enhancement of 5hmC level in HCT-116 cells. Furthermore, hinokitiol reduces methylation status and restores mRNA expression of MGMT, CHST10, and BTG4 genes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 499-44-5
Appearance Solid
Molecular Weight 164.20
Formel C₁₀H₁₂O₂
Color Off-white to yellow
SMILES

O=C1C(O)=CC(C(C)C)=CC=C1
Synonyms

β-Thujaplicin
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (9)

All

Sort by:

Journal Impact Factor

Phytomedicine

Hinokitiol ameliorates MASH in mice by therapeutic targeting of hepatic Nrf2 and inhibiting hepatocyte ferroptosis. [Abstract]

2025 Feb 5:139:156472. PMID: 39922149
Eur J Pharmacol

Hinokitiol protects gastric injury from ethanol exposure via its iron sequestration capacity. [Abstract]

2024 Mar 5:966:176340. PMID: 38244759
Int Immunopharmacol

Hinokitiol inhibits RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced bone loss in vivo. [Abstract]

2021 Jul:96:107619. PMID: 33831806
Microorganisms

Biochanin A Exerts Broad-Spectrum Antiviral Activity Against Coronaviruses via Activating the AMPK/Nrf2/GSH Pathway. [Abstract]

2026 Apr 9;14(4):851. PMID: 42075248
Sci Rep

UHRF1 promotes epithelial-mesenchymal transition mediating renal fibrosis by activating the TGF-β/SMAD signaling pathway. [Abstract]

2025 Jan 27;15(1):3346. PMID: 39870702
Cell Stress Chaperones

ALDH3B1 protects interfollicular epidermal cells against lipid peroxidation via the NRF2 pathway. [Abstract]

2022 Nov;27(6):703-715. PMID: 36327089
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Research Square Print

2022 Jul.
Oxid Med Cell Longev

Ferroportin-Dependent Iron Homeostasis Protects against Oxidative Stress-Induced Nucleus Pulposus Cell Ferroptosis and Ameliorates Intervertebral Disc Degeneration In Vivo. [Abstract]

2021 Feb 10:2021:6670497. PMID: 33628376

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (609.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

6.0901 mL

30.4507 mL

60.9013 mL

5 mM

1.2180 mL

6.0901 mL

12.1803 mL

10 mM

0.6090 mL

3.0451 mL

6.0901 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (15.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (15.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (15.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 10 mg/mL (60.90 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

U87MG and T98G glioma cells are cultured in Dulbecco's modified Eagle's medium with Ham's F12 medium (DMEM/F-12) containing 10% fetal bovine serum. Cell viability is determined using MTT to evaluate the cytotoxicity of hinokitiol. Cells are seeded in 24-well plates (1×10⁵ cells/well) in the presence of various concentration of hinokitiol or vehicle at 37°C for 24 h followed by incubation with MTT reagent. The blue formazan crystals of viable cells are dissolved in DMSO and then evaluated spectrophotometrically at 570 nm. DMSO-treated group is set as 100%, and data are presented as percentage of DMSO control. IC₅₀ values are calculated by the GraFit software.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Ouyang WC, et al. Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation. Cancer Chemother Pharmacol. 2017 Aug;80(2):411-419. [Content Brief]

[2]. Seo JS, et al. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol. 2017 Feb 27;18(1):14. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	6.0901 mL	30.4507 mL	60.9013 mL	152.2534 mL
	5 mM	1.2180 mL	6.0901 mL	12.1803 mL	30.4507 mL
	10 mM	0.6090 mL	3.0451 mL	6.0901 mL	15.2253 mL
	15 mM	0.4060 mL	2.0300 mL	4.0601 mL	10.1502 mL
	20 mM	0.3045 mL	1.5225 mL	3.0451 mL	7.6127 mL
	25 mM	0.2436 mL	1.2180 mL	2.4361 mL	6.0901 mL
	30 mM	0.2030 mL	1.0150 mL	2.0300 mL	5.0751 mL
	40 mM	0.1523 mL	0.7613 mL	1.5225 mL	3.8063 mL
	50 mM	0.1218 mL	0.6090 mL	1.2180 mL	3.0451 mL
	60 mM	0.1015 mL	0.5075 mL	1.0150 mL	2.5376 mL
	80 mM	0.0761 mL	0.3806 mL	0.7613 mL	1.9032 mL
	100 mM	0.0609 mL	0.3045 mL	0.6090 mL	1.5225 mL

Keywords

Hinokitiol

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Hinokitiol

Anti-Infection Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Tibetan Medicine Compound Library

RO5 Drug-like Natural Product Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Hinokitiol

Alle DNA Methyltransferase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (9)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Hinokitiol Related Classifications

HY-B2230 Related Classifications